Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Phase 2 Active not recruiting 48 enrolled Memorial Sloan Kettering Cancer Center

NaSingle-groupOpen-labelTreatment

Summary

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

Timeline

Start: 2020-07-09
Primary completion: 2026-07
Completion: 2026-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Clindamycin	Unknown	1 %	Topical
Subject	Triamcinolone Acetonide	Other / unclassified	0.01 %	Topical

Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

Summary

Timeline

Drugs

Indications